Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

The FDA’s move to lift the hold on Zentalis Pharmaceuticals’ sole clinical-stage drug may have been good news for the biotech ...

Having shown last week that its opioid alternative can reduce post-surgery pain, Tris Pharma is back with another slice of ...

A judge has ruled against investor Alcon Research on the matter of blocking investee Aurion Biotech from debuting on the ...

Imperative Care has received a green light from the FDA for its large-bore catheter to help remove stroke-causing blood clots ...

Philips is parting ways with its worldwide emergency care business, including its catalog of automated external ...

BioAge Labs has given up on its lead obesity candidate. Weeks after stopping a trial in response to phase 2 data, the biotech ...

Demand slipped for several large contract research organizations last year, and a new report from William Blair analysts suggests these firms should brace for a similar R&D landscape in 2025.

Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

Just days after President Trump imposed broad restrictions on communications, meetings, travel and public appearances at the ...

After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...

Transforming life sciences with AI, powered by Salesforce Life Sciences Cloud | Drug development and commercialization leads ...